Literature DB >> 23015684

Epithelial eotaxin-2 and eotaxin-3 expression: relation to asthma severity, luminal eosinophilia and age at onset.

John M Coleman1, Chetan Naik, Fernando Holguin, Anuradha Ray, Prabir Ray, John B Trudeau, Sally E Wenzel.   

Abstract

BACKGROUND: Eosinophilic inflammation is implicated in asthma. Eotaxin 1-3 regulate eosinophil trafficking into the airways along with other chemotactic factors. However, the epithelial and bronchoalveolar lavage (BAL) cell expression of these chemokines in relation to asthma severity and eosinophilic phenotypes has not been addressed.
OBJECTIVE: To measure the expression of the three eotaxin isoforms in bronchoscopically obtained samples and compare them with clinically relevant parameters between normal subjects and patients with asthma.
METHODS: Normal subjects and patients with asthma of varying severity recruited through the Severe Asthma Research Program underwent clinical assessment and bronchoscopy with airway brushing and BAL. Eotaxin 1-3 mRNA/protein were measured in epithelial and BAL cells and compared with asthma severity, control and eosinophilic inflammation.
RESULTS: Eotaxin-2 and eotaxin-3 mRNA and eotaxin-2 protein were increased in airway epithelial brushings from patients with asthma and were highest in cases of severe asthma (p values 0.0155, 0.0033 and 0.0006, respectively), with eotaxin-2 protein increased with age at onset. BAL cells normally expressed high levels of eotaxin-2 mRNA/protein but BAL fluid levels of eotaxin-2 were lowest in severe asthma. Epithelial eotaxin-2 and eotaxin-3 mRNA/protein was associated with sputum eosinophilia, lower forced expiratory volume in 1 s and more asthma exacerbations. Airway epithelial cell eotaxin-2 protein differed by asthma severity only in those with late onset disease, and tended to be highest in those with late onset eosinophilic asthma.
CONCLUSIONS: Epithelial eotaxin-2 and 3 are increased in asthma and severe asthma. Their expression may contribute to luminal migration of eosinophils, especially in later onset disease, asthma control and severity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23015684      PMCID: PMC3652589          DOI: 10.1136/thoraxjnl-2012-201634

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  32 in total

Review 1.  Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-12       Impact factor: 21.405

2.  Factors associated with persistent airflow limitation in severe asthma.

Authors:  A ten Brinke; A H Zwinderman; P J Sterk; K F Rabe; E H Bel
Journal:  Am J Respir Crit Care Med       Date:  2001-09-01       Impact factor: 21.405

3.  15-Lipoxygenase 1 interacts with phosphatidylethanolamine-binding protein to regulate MAPK signaling in human airway epithelial cells.

Authors:  Jinming Zhao; Valerie B O'Donnell; Silvana Balzar; Claudette M St Croix; John B Trudeau; Sally E Wenzel
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-09       Impact factor: 11.205

4.  Eotaxin-3 but not eotaxin gene expression is upregulated in asthmatics 24 hours after allergen challenge.

Authors:  N Berkman; S Ohnona; F K Chung; R Breuer
Journal:  Am J Respir Cell Mol Biol       Date:  2001-06       Impact factor: 6.914

5.  Interleukin-13 upregulates eotaxin expression in airway epithelial cells by a STAT6-dependent mechanism.

Authors:  S Matsukura; C Stellato; S N Georas; V Casolaro; J R Plitt; K Miura; S Kurosawa; U Schindler; R P Schleimer
Journal:  Am J Respir Cell Mol Biol       Date:  2001-06       Impact factor: 6.914

6.  Eotaxin expression after segmental allergen challenge in subjects with atopic asthma.

Authors:  C M Lilly; H Nakamura; O I Belostotsky; K J Haley; E A Garcia-Zepeda; A D Luster; E Israel
Journal:  Am J Respir Crit Care Med       Date:  2001-06       Impact factor: 21.405

7.  Mast cell phenotype, location, and activation in severe asthma. Data from the Severe Asthma Research Program.

Authors:  Silvana Balzar; Merritt L Fajt; Suzy A A Comhair; Serpil C Erzurum; Eugene Bleecker; William W Busse; Mario Castro; Benjamin Gaston; Elliot Israel; Lawrence B Schwartz; Douglas Curran-Everett; Charity G Moore; Sally E Wenzel
Journal:  Am J Respir Crit Care Med       Date:  2010-09-02       Impact factor: 21.405

8.  Differential regulation of epithelial-derived C-C chemokine expression by IL-4 and the glucocorticoid budesonide.

Authors:  C Stellato; S Matsukura; A Fal; J White; L A Beck; D Proud; R P Schleimer
Journal:  J Immunol       Date:  1999-11-15       Impact factor: 5.422

9.  Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study.

Authors:  Mario Castro; Sameer Mathur; Frederick Hargreave; Louis-Philippe Boulet; Fang Xie; James Young; H Jeffrey Wilkins; Timothy Henkel; Parameswaran Nair
Journal:  Am J Respir Crit Care Med       Date:  2011-08-18       Impact factor: 21.405

10.  Safety of investigative bronchoscopy in the Severe Asthma Research Program.

Authors:  Wendy C Moore; Michael D Evans; Eugene R Bleecker; William W Busse; William J Calhoun; Mario Castro; Kian Fan Chung; Serpil C Erzurum; Douglas Curran-Everett; Raed A Dweik; Benjamin Gaston; Mark Hew; Elliot Israel; Martin L Mayse; Rodolfo M Pascual; Stephen P Peters; Lori Silveira; Sally E Wenzel; Nizar N Jarjour
Journal:  J Allergy Clin Immunol       Date:  2011-04-15       Impact factor: 10.793

View more
  36 in total

1.  Farnesyltransferase Inhibition Exacerbates Eosinophilic Inflammation and Airway Hyperreactivity in Mice with Experimental Asthma: The Complex Roles of Ras GTPase and Farnesylpyrophosphate in Type 2 Allergic Inflammation.

Authors:  Jennifer M Bratt; Kevin Y Chang; Michelle Rabowsky; Lisa M Franzi; Sean P Ott; Simone Filosto; Tzipora Goldkorn; Muhammad Arif; Jerold A Last; Nicholas J Kenyon; Amir A Zeki
Journal:  J Immunol       Date:  2018-04-27       Impact factor: 5.422

Review 2.  Emerging molecular phenotypes of asthma.

Authors:  Anuradha Ray; Timothy B Oriss; Sally E Wenzel
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-10-17       Impact factor: 5.464

3.  Eotaxin-2 increased toll-like receptor 4 expression in endothelial cells in vitro and exacerbates high-cholesterol diet-induced atherogenesis in vivo.

Authors:  Chien-Sung Tsai; Chun-Yao Huang; Chien-Ho Chen; Yi-Wen Lin; Chun-Ming Shih; Nai-Wen Tsao; Kuang-Hsing Chiang; Chi-Yuan Lee; Hellen Jeng; Feng-Yen Lin
Journal:  Am J Transl Res       Date:  2016-12-15       Impact factor: 4.060

4.  IL-27 and type 2 immunity in asthmatic patients: association with severity, CXCL9, and signal transducer and activator of transcription signaling.

Authors:  Min Xie; Anthony T Mustovich; Yi Jiang; John B Trudeau; Anuradha Ray; Prabir Ray; Haizhen Hu; Fernando Holguin; Bruce Freeman; Sally E Wenzel
Journal:  J Allergy Clin Immunol       Date:  2014-10-11       Impact factor: 10.793

5.  Eotaxin-2 induces monocytic apoptosis in patients who have undergone coronary artery bypass surgery and in THP-1 cells in vitro regulated by thrombomodulin.

Authors:  Yi-Wen Lin; Chun-Yao Huang; Chun-Min Shih; Yi-Ting Tsai; Chin-Sheng Lin; Chih-Yuan Lin; Chi-Yuan Li; Shih-Hurng Loh; Cheng-Yen Lin; Feng-Yen Lin; Chien-Sung Tsai
Journal:  Am J Transl Res       Date:  2018-10-15       Impact factor: 4.060

Review 6.  Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations.

Authors:  Diego Bagnasco; Matteo Ferrando; Marco Caminati; Alice Bragantini; Francesca Puggioni; Gilda Varricchi; Giovanni Passalacqua; Giorgio Walter Canonica
Journal:  Drug Saf       Date:  2017-07       Impact factor: 5.606

Review 7.  Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.

Authors:  Behzad Yeganeh; Emilia Wiechec; Sudharsana R Ande; Pawan Sharma; Adel Rezaei Moghadam; Martin Post; Darren H Freed; Mohammad Hashemi; Shahla Shojaei; Amir A Zeki; Saeid Ghavami
Journal:  Pharmacol Ther       Date:  2014-02-26       Impact factor: 12.310

8.  DNA nanoparticle-mediated thymulin gene therapy prevents airway remodeling in experimental allergic asthma.

Authors:  Adriana L da Silva; Sabrina V Martini; Soraia C Abreu; Cynthia dos S Samary; Bruno L Diaz; Sandra Fernezlian; Vanessa Karen de Sá; Vera Luiza Capelozzi; Nicholas J Boylan; Rodolfo Gustavo Goya; Jung Soo Suk; Patricia R M Rocco; Justin Hanes; Marcelo M Morales
Journal:  J Control Release       Date:  2014-02-17       Impact factor: 9.776

9.  Chemotaxis of bone marrow derived eosinophils in vivo: a novel method to explore receptor-dependent trafficking in the mouse.

Authors:  Eva M Sturm; Kimberly D Dyer; Caroline M Percopo; Akos Heinemann; Helene F Rosenberg
Journal:  Eur J Immunol       Date:  2013-06-14       Impact factor: 5.532

Review 10.  Severe Asthma in Children: Lessons Learned and Future Directions.

Authors:  Anne M Fitzpatrick
Journal:  J Allergy Clin Immunol Pract       Date:  2016 Jan-Feb
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.